The Noah Report homepage has 60 new headlines every 24 hours – click here to see it.
The FDA is replacing “animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods.”
According to the FDA, “The FDA’s animal testing requirement will be reduced, refined, or potentially replaced using a range of approaches, including AI-based computational models of toxicity and cell lines and organoid toxicity testing in a laboratory setting (so-called New Approach Methodologies or NAMs data).”
Today, the U.S. Food and Drug Administration is taking a groundbreaking step to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods. The new approach is
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!